Outpatient PC is associated with benefits among patients with PDRD compared with standard care alone. 5 key findings →
Participants: 584 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
75/100
While genome wide association studies (GWASs) of Alzheimer's Disease (AD) in European (EUR) ancestry cohorts have identified approximately 83 potentially independent AD risk loci, progress in non-European populations has lagged. 5 key findings →
Design: meta-analysis Participants: 4,385 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
At 6 months, compared with usual care, participants receiving the intervention had better QOL (QOL-AD score, 0.09 [95% CI, -0.63 to 0.82] vs -0.88 [95% CI, -1.62 to -0.13]; treatment effect estimate, 0.97; 95% CI, 0.07-1.86; P = .03). 4 key findings →
Participants: 612 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Most cross-sectional and longitudinal studies suggest an association between cognitive impairment and CKD. 4 key findings →
Design: meta-analysis Participants: 54,779 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This cohort study found that COVID-19 mortality decreased over time during 2020 and that patient demographic characteristics and comorbidities were associated with higher clinical severity. 5 key findings →
Design: cohort study Participants: 174 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Out of hospital cardiac arrest (OHCA) remains a significant public health problem with high mortality and morbidity. 5 key findings →
Design: meta-analysis Participants: 1,410 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Voxel-wise contrasts against controls (at P < 0.05 family-wise error corrected) showed that (18)F-AV1451 and (18)F-FDG patterns in patients with posterior cortical atrophy ('visual variant of Alzheimer's disease', n = 7) specifically targeted the clinically affected posterior brain regions, while (11)C-PiB bound diffusely throughout the neocortex. 5 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 172 patients were included (86 each in the sotatercept and placebo groups). 5 key findings →
Design: clinical trial Participants: 172 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The objective is to identify risk factors associated with PASC/long-COVID diagnosis. 5 key findings →
Design: case-control study Participants: 8,325 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The online SiD decision aid increased preparation for decision making about firearm access in this sample of ADRD caregivers in the United States. 5 key findings →
Design: RCT Participants: 500 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Obicetrapib significantly slowed AD biomarker progression over 12 months in participants with ASCVD, with the greatest effects in ApoE4 carriers. 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
While sex differences were not apparent at asymptomatic stages, females showed more rapid declines across all outcomes in symptomatic stages compared to males. 5 key findings →
Design: longitudinal study Participants: 337 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
62/100
Comparisons of ADNC in typical amnestic versus atypical aphasic dementia and of TDP in type A versus type C revealed fundamental biological and clinical differences, suggesting that members of each pair may constitute distinct clinicopathologic entities despite identical downstream proteinopathies. 1 key finding →
Design: longitudinal study Participants: 68 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These findings have implications for clinical practice and suggest that presence of a caregiver may be an important modifying variable on patient outcomes to examine in future research. 3 key findings →
Design: randomized controlled trial Participants: 210 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There was strong agreement regarding the definition of the core clinico-radiological syndrome, meaning that the current consensus statement should be regarded as a refinement, development, and extension of previous single-center PCA criteria rather than any wholesale alteration or redescription of the syndrome. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From 11 295 literature citations associated with 10 PICO questions, 20 relevant studies were identified. 1 key finding →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The S@H study is the first randomized trial of a firearm safety decision aid for ADRD caregivers. 3 key findings →
Design: randomized controlled trial Participants: 117 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Sex or gender differences in the risk of Alzheimer's disease and related dementias (ADRD) differ by world region, suggesting that there are potentially modifiable risk factors for intervention. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Undiagnosed dementia is common and associated with increased mortality, identifying a vulnerable population missed by current diagnostic pathways. 3 key findings →
Design: cohort Participants: 13,142 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The average PM2.5 levels in the IHS counties were lower than those in all US counties, while the mean O3 levels in the IHS counties were higher than the US counties. 4 key findings →
Design: cohort study Participants: 26,871 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
53/100
Compared with white patients, black patients were less likely to have heart failure with preserved systolic function. 3 key findings →
Participants: 11,994 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive decline in chronic diabetic patients is a less investigated topic. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
52/100
We analyzed CSF concentrations of neurogranin, β-amyloid (Aβ42), phosphorylated tau (p-tau), and total tau (t-tau) among 132 neurologically normal older adults (mean 64.5, range 55-85), along with bilateral hippocampal volumes and a measure of episodic memory (Auditory Verbal Learning Test, delayed recall). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
52/100
Adjudicated AKI, which was largely mild and reversible, was independently associated with increased risk of probable dementia and the composite of probable dementia and MCI in older adults at high cardiovascular risk. 5 key findings →
Design: cohort study Participants: 270 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
SiD represents a new resource for promoting safety among people with dementia, and high acceptability was achieved in a pilot trial. 2 key findings →
Design: clinical trial Participants: 203 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →